Literature DB >> 33306276

Pathology of childhood rhabdomyosarcoma: A consensus opinion document from the Children's Oncology Group, European Paediatric Soft Tissue Sarcoma Study Group, and the Cooperative Weichteilsarkom Studiengruppe.

Erin R Rudzinski1, Anna Kelsey2, Christian Vokuhl3, Corinne M Linardic4,5, Janet Shipley6, Simone Hettmer7, Ewa Koscielniak8, Douglas S Hawkins9, Gianni Bisogno10.   

Abstract

The diagnosis and classification of rhabdomyosarcoma (RMS) has undergone several shifts over the last 30 years. While the main diagnostic categories remained the same, changes in the histologic criteria necessary for diagnosis, as well as varied reliance on immunohistochemical and molecular data over time, have created confusion, particularly regarding how these shifts impacted risk stratification and enrollment onto clinical trials. The goal of this report is to review the evolution and current status of RMS diagnosis, focusing on diagnostic criteria in the Children's Oncology Group (COG), the European Paediatric Soft Tissue Sarcoma Group (EpSSG), and the Cooperative Weichteilsarkom Studiengruppe (CWS). In addition, we emphasize research tools used to classify RMS and address biological questions within current clinical trials run by each group. The INternational Soft Tissue SaRcoma ConsorTium (INSTRuCT) initiative will maximize potential to optimize risk stratification by recognizing and accounting for differences in historical data and current practices.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  pathology; pediatric; rhabdomyosarcoma

Mesh:

Year:  2020        PMID: 33306276     DOI: 10.1002/pbc.28798

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  7 in total

Review 1.  An update on rhabdomyosarcoma risk stratification and the rationale for current and future Children's Oncology Group clinical trials.

Authors:  Josephine H Haduong; Christine M Heske; Wendy Allen-Rhoades; Wei Xue; Lisa A Teot; David A Rodeberg; Sarah S Donaldson; Aaron Weiss; Douglas S Hawkins; Rajkumar Venkatramani
Journal:  Pediatr Blood Cancer       Date:  2022-02-07       Impact factor: 3.167

2.  Creating a data commons: The INternational Soft Tissue SaRcoma ConsorTium (INSTRuCT).

Authors:  Kirk D Wyatt; Suzi Birz; Douglas S Hawkins; Veronique Minard-Colin; David A Rodeberg; Monika Sparber-Sauer; Gianni Bisogno; Ewa Koscielniak; Gian Luca De Salvo; Martin Ebinger; Johannes H M Merks; Suzanne L Wolden; Wei Xue; Samuel L Volchenboum
Journal:  Pediatr Blood Cancer       Date:  2022-08-15       Impact factor: 3.838

3.  Deep Learning of Rhabdomyosarcoma Pathology Images for Classification and Survival Outcome Prediction.

Authors:  Xinyi Zhang; Shidan Wang; Erin R Rudzinski; Saloni Agarwal; Ruichen Rong; Donald A Barkauskas; Ovidiu Daescu; Lauren Furman Cline; Rajkumar Venkatramani; Yang Xie; Guanghua Xiao; Patrick Leavey
Journal:  Am J Pathol       Date:  2022-04-04       Impact factor: 5.770

4.  The Effect of Direct and Indirect EZH2 Inhibition in Rhabdomyosarcoma Cell Lines.

Authors:  Andreas Schmidt; Lucas Behrendt; Jana Eybe; Steven W Warmann; Sabine Schleicher; Joerg Fuchs; Evi Schmid
Journal:  Cancers (Basel)       Date:  2021-12-23       Impact factor: 6.639

5.  Long-Term Clinical Outcome and Prognostic Factors of Children and Adolescents with Localized Rhabdomyosarcoma Treated on the CWS-2002P Protocol.

Authors:  Ewa Koscielniak; Bernd Blank; Christian Vokuhl; Bernarda Kazanowska; Ruth Ladenstein; Felix Niggli; Gustaf Ljungman; Rupert Handgretinger; Guido Seitz; Jörg Fuchs; Birgit Fröhlich; Monika Scheer; Rüdiger Wessalowski; Irene Schmid; Monika Sparber-Sauer; Thomas Klingebiel
Journal:  Cancers (Basel)       Date:  2022-02-11       Impact factor: 6.639

6.  Importance of histopathological analysis and molecular genetics in a rare neonatal case of rhabdomyosarcoma.

Authors:  Prudence Gramp; Tania Zappala; Lena Von Schuckmann; Diane Payton; Laura Wheller
Journal:  Australas J Dermatol       Date:  2022-05-02       Impact factor: 2.481

Review 7.  Pediatric Rhabdomyosarcoma: Epidemiology and Genetic Susceptibility.

Authors:  Bailey A Martin-Giacalone; P Adam Weinstein; Sharon E Plon; Philip J Lupo
Journal:  J Clin Med       Date:  2021-05-09       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.